{"id":250034,"date":"2025-11-04T00:00:00","date_gmt":"2025-11-04T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/products\/research-reports\/report\/epidim0132-biopharma-vitiligo-epidemiology-mature-markets\/"},"modified":"2026-04-23T11:16:17","modified_gmt":"2026-04-23T11:16:17","slug":"epidim0132-biopharma-vitiligo-epidemiology-mature-markets","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidim0132-biopharma-vitiligo-epidemiology-mature-markets\/","title":{"rendered":"Vitiligo &#8211; Epidemiology &#8211; Mature Markets"},"content":{"rendered":"<p>Clarivate Epidemiology&#8217;s coverage of vitiligo comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the diagnosed prevalence of vitiligo for each country, as well as annualized case counts projected to the national population.<\/p>\n<p>Patient populations are forecast over a period of 20 years.<\/p>\n<p>Clarivate Epidemiology&#8217;s vitiligo forecast will answer the following question:<\/p>\n<ul>\n<li>How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of vitiligo over the forecast period?<\/li>\n<\/ul>\n<p>All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to <abbr data-abbreviation-entity=\"10739\" title=\"Microsoft\">MS<\/abbr> Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.<\/p>\n<p>In total, Clarivate Epidemiology forecasts vitiligo patient populations, as follows:<\/p>\n<ul>\n<li>Diagnosed<span> vitiligo prevalent cases.<\/span><\/li>\n<li>Diagnosed\u00a0vitiligo prevalent cases by subtypes.<\/li>\n<li>Diagnosed vitiligo prevalent cases by total body surface area (TBSA).<\/li>\n<li>Diagnosed vitiligo prevalent cases by comorbidity.<\/li>\n<\/ul>\n<p>Note: Coverage may vary by country.<\/p>\n","protected":false},"template":"","class_list":["post-250034","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-product-epidemiology","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/250034","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/250034\/revisions"}],"predecessor-version":[{"id":573823,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/250034\/revisions\/573823"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=250034"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}